Maria Rizza
Cardiovascular Disease · Fountain Valley, CANPI 1689638280
Payments from drug & device makers
Across 138 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$485
- Amgen$457
- Sanofi-aventis U.S. LLC$225
- E.r. Squibb & Sons, L.L.C.$196
- Otsuka America Pharmaceutical, Inc.$130
- Regeneron Healthcare Solutions, Inc.$129
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,661100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,669 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Flecainide Acetate | 13 | $372 |
| Ezetimibe | 13 | $211 |
| Losartan Potassium | 18 | $174 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Fountain Valley
- Vinod MalhotraFountain Valley$1.5M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.